CD47 and atherosclerosis: Blocking the CD47–SIRPa interaction then promotes phagocytosis and PrCR (26, 28, 65, 66, 67), and in atherosclerosis it enhances phagocytic removal of diseased vascular cells and halts disease progression (68).